This book, written by respected experts, discusses in detail the latest developments in targeted therapy for hematologic malignancies using small molecules. It covers a wide range of small molecules including tyrosine kinase inhibitors, immunomodulatory drugs, the IDH-2 inhibitor enasidenib, the BCL-2 inhibitor venetoclax, and the proteasome inhibitor carfilzomib. For each molecule, aspects such as the chemical structure, mechanism of action, drug targets, drug interactions, preclinical studies, clinical trials, treatment applications, and toxicity are discussed.

Extensive research into the molecular mechanisms of cancer has heralded a new age of targeted therapy. The field of precision cancer therapy is now growing rapidly, and the advances being made will mean significant changes in the treatment algorithms for cancer patients. Numerous novel targets that are crucial for the survival of cancer cells can be attacked by small molecules such as protein tyrosine kinase inhibitors. An accompanying volume addresses the use of small molecules in oncology, and the two volumes together represent the third edition of the book originally published under the same title.

Discusses the most recent developments in targeted therapy in hematology using small molecules Describes chemical structure, mechanism of action, drug targets, and drug interactions Examines preclinical studies, clinical trials, and treatment applications

Autorentext
Uwe Martens, Prof. Dr. med., is chair of the Cancer Center Heilbronn-Franken and head of the Department of Hematology and Oncology at the SLK Clinic Heilbronn, which is an academic teaching hospital of the University of Heidelberg. He graduated in Medicine from the University of Freiburg and continued his medical and scientific training at the Medical University Center in Freiburg and at the BC Cancer Research Center in Vancouver. His scientific focus is the development of personalized cancer therapy and immunotherapy. He is a co-founder of the MOLIT Institute for Personalized Medicine at the science and technology park in Heilbronn, which aims to rapidly translate precision medicine into standard care.

Inhalt
Imatinib .- Dasatinib .- Nilotinib .- Bosutinib .- Ponatinib .- Ruxolitinib .- Ibrutinib .- Lenalidomide .- Pomalidomide .- Enasidenib .- Midostaurin .- Alectinib .- Osimertinib .- Venetoclax .- Idelaslisib .- Carfilzomib .- Acalabrutinib.